EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community

Mitsuhiro Watanabe, Shinya Fujiki, Yuji Okura, Chie Toshikawa, Mayuko Ikarashi, Chizuko Kanbayashi, Koji Kaneko, Akira Kikuchi, Eiko Sakata, Keiichi Tsuchida, Kazuyuki Ozaki, Kazuki Moro und 9 weitere

Breast Cancer · 2024

DOI: 10.1007/s12282-024-01623-0 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Breast Cancer, 2024. Verfasst von Mitsuhiro Watanabe und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Trastuzumab, Anthracyclines, Cardiomyopathies. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trastuzumab has improved breast cancer (BC) prognosis and reduced anthracycline use. However, the characteristic changes of anthracycline-related cardiomyopathy (ARCM) in patients with BC remain unclear. We aimed to update our understanding of ARCM in the trastuzumab era. METHODS This retrospective observational cohort study included 2959 patients with BC treated with anthracyclines at three regional cancer centers in Niigata City between 1990 and 2020. Seventy-five patients (2.5%) developed ARCM and were categorized into two groups: pre- 2007 (early phase) and post-2007 (late phase), corresponding to before and during the trastuzumab era in Japan.

Results

ARCM incidence peaked at 6% in the 1990s, then decreased and stabilized at 2% until the 2010s. Survivors of anthracycline-treated BC increased more rapidly in the late phase, with four times as many patients with ARCM compared to the end of the early phase (26 and six, respectively). Although the rate of change in accumulation from the early phase to the late phase was slight in the anthracycline-treated BC group, it was more pronounced in the ARCM group ( P < 0.001). Mean anthracycline use in the late phase was significantly lower than in the early phase (307 vs. 525 mg/m 2 , P < 0.001). Five-year survival rates in the late phase tended to be higher than early phase (45% and 28%, respectively. P = 0.058). Human epidermal growth factor receptor type 2 (HER2) positivity with trastuzumab therapy in the late phase was an independent predictor for mortality within 10 years (hazard ratio = 0.24, 95% confidence interval: 0.10–0.56; P = 0.001).

Conclusions

HER2-positive patients with ARCM receiving trastuzumab therapy had a better prognosis than HER2-positive and HER2-negative patients with ARCM not receiving trastuzumab therapy, and this trend has been increasing in the trastuzumab era. These findings highlight the importance of HER2-targeted treatments in improving prognosis for BC patients with ARCM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsTrastuzumabAnthracyclinesCardiomyopathiesCancer SurvivorsHumansFemaleRetrospective StudiesMiddle AgedJapanAdultAgedIncidencePrognosisAntineoplastic Agents, ImmunologicalEast Asian People

Stichwörter der Autor:innen

AnthracyclineCardiotoxicityHuman epidermal growth factor receptor type 2Secular trendTrastuzumab

Substanzen

TrastuzumabAnthracyclinesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Department of Onco-Cardiology, Niigata Cancer Center Hospital, 2-15-3 Kawagishi-cho, Chuo-ku, Niigata, 951-8560, Japan. okuray@niigata-cc.jp.
  • Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
  • Department of Breast Surgery, Niigata City General Hospital, Niigata, Japan.
  • Department of Breast Oncology, Niigata Cancer Center Hospital, Niigata, Japan.
  • Department of Gynecology, Niigata Cancer Center Hospital, Niigata, Japan.

Zitieren

APA

Watanabe, M., Fujiki, S., Okura, Y., Toshikawa, C., Ikarashi, M., Kanbayashi, C., Kaneko, K., Kikuchi, A., Sakata, E., Tsuchida, K., Ozaki, K., Moro, K., Kubota, N., Kashimura, T., Moriyama, M., Sato, N., Tanabe, N., Koyama, Y., Wakai, T., …, & Inomata, T. (2024). Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community. Breast Cancer. https://doi.org/10.1007/s12282-024-01623-0

Vancouver

Watanabe M, Fujiki S, Okura Y, Toshikawa C, Ikarashi M, Kanbayashi C, et al. Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community. Breast Cancer. 2024. doi:10.1007/s12282-024-01623-0

BibTeX
@article{Watanabe2024,
  author = {Watanabe, Mitsuhiro and Fujiki, Shinya and Okura, Yuji and Toshikawa, Chie and Ikarashi, Mayuko and Kanbayashi, Chizuko and Kaneko, Koji and Kikuchi, Akira and Sakata, Eiko and Tsuchida, Keiichi and Ozaki, Kazuyuki and Moro, Kazuki and Kubota, Naoki and Kashimura, Takeshi and Moriyama, Masato and Sato, Nobuaki and Tanabe, Naohito and Koyama, Yu and Wakai, Toshifumi and Saijo, Yasuo and Inomata, Takayuki},
  title = {Increasing survivors of anthracycline-related cardiomyopathy with breast cancer in trastuzumab era: thirty-one-year trends in a Japanese Community},
  journal = {Breast Cancer},
  year = {2024},
  doi = {10.1007/s12282-024-01623-0}
}
Kostenlos starten →